JP2013511966A - 単一特異性ポリペプチド試薬 - Google Patents

単一特異性ポリペプチド試薬 Download PDF

Info

Publication number
JP2013511966A
JP2013511966A JP2012540419A JP2012540419A JP2013511966A JP 2013511966 A JP2013511966 A JP 2013511966A JP 2012540419 A JP2012540419 A JP 2012540419A JP 2012540419 A JP2012540419 A JP 2012540419A JP 2013511966 A JP2013511966 A JP 2013511966A
Authority
JP
Japan
Prior art keywords
igg
cad
seq
fusion polypeptide
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012540419A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013511966A5 (https=
Inventor
ロベルト・ポッペ
Original Assignee
オルゲンテック・ディアグノスティカ・ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オルゲンテック・ディアグノスティカ・ゲーエムベーハー filed Critical オルゲンテック・ディアグノスティカ・ゲーエムベーハー
Publication of JP2013511966A publication Critical patent/JP2013511966A/ja
Publication of JP2013511966A5 publication Critical patent/JP2013511966A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/528—CH4 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2012540419A 2009-11-27 2010-11-24 単一特異性ポリペプチド試薬 Pending JP2013511966A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102009047243A DE102009047243A1 (de) 2009-11-27 2009-11-27 Monospezifische Polypeptidreagenzien
DE102009047243.6 2009-11-27
PCT/EP2010/068134 WO2011064257A2 (de) 2009-11-27 2010-11-24 Monospezifische polypeptidreagenzien

Publications (2)

Publication Number Publication Date
JP2013511966A true JP2013511966A (ja) 2013-04-11
JP2013511966A5 JP2013511966A5 (https=) 2014-01-09

Family

ID=43589669

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012540419A Pending JP2013511966A (ja) 2009-11-27 2010-11-24 単一特異性ポリペプチド試薬

Country Status (8)

Country Link
US (2) US9163079B2 (https=)
EP (1) EP2504359B1 (https=)
JP (1) JP2013511966A (https=)
AU (1) AU2010323144B2 (https=)
CA (1) CA2782016C (https=)
DE (1) DE102009047243A1 (https=)
DK (1) DK2504359T3 (https=)
WO (1) WO2011064257A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022528030A (ja) * 2019-01-07 2022-06-08 トーマス・ジェファーソン・ユニバーシティ 多機能性融合タンパク質及びその使用

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2413087T3 (es) 2006-06-13 2013-07-15 Oncomed Pharmaceuticals, Inc. Composiciones y métodos para el diagnóstico y tratamiento del cáncer
WO2008091641A2 (en) 2007-01-24 2008-07-31 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
CN102112490B (zh) 2008-07-08 2014-10-22 昂考梅德药品有限公司 Notch1受体结合剂和其使用方法
DE102009047243A1 (de) * 2009-11-27 2011-06-01 Orgentec Diagnostika Gmbh Monospezifische Polypeptidreagenzien
WO2013156054A1 (en) * 2012-04-16 2013-10-24 Universität Stuttgart The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity
US20170023576A1 (en) * 2014-04-04 2017-01-26 Oncomed Pharmaceuticals, Inc. Notch3 antibodies and uses thereof
WO2018037092A1 (en) * 2016-08-26 2018-03-01 Sanofi Multispecific antibodies facilitating selective light chain pairing
CA3042236A1 (en) 2016-10-28 2018-05-03 Washington University Anti-apoe antibodies
AU2020301529B2 (en) 2019-06-24 2026-03-26 Universität Stuttgart TNFR2 agonists with improved stability

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000516452A (ja) * 1996-07-16 2000-12-12 プリュックテュン，アンドレアス 可溶性が増大した免疫グロブリンスーパーファミリードメインおよびフラグメント
JP2003501096A (ja) * 1999-06-07 2003-01-14 ネオルクス コーポレイション ストレプトアビジン発現性遺伝子融合およびその使用方法
WO2005017148A1 (en) * 2003-07-26 2005-02-24 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
WO2008131242A1 (en) * 2007-04-18 2008-10-30 Zymogenetics, Inc. Single chain fc, methods of making and methods of treatment
JP2009544300A (ja) * 2006-07-25 2009-12-17 ユセベ ファルマ ソシエテ アノニム 単鎖Ｆｃポリペプチド

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0627932B1 (en) 1992-11-04 2002-05-08 City Of Hope Antibody construct
US6015662A (en) 1996-01-23 2000-01-18 Abbott Laboratories Reagents for use as calibrators and controls
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
US6151296A (en) 1997-06-19 2000-11-21 Qualcomm Incorporated Bit interleaving for orthogonal frequency division multiplexing in the transmission of digital signals
DE10001372A1 (de) 2000-01-14 2001-08-02 Deutsches Krebsforsch Anti-CD3-Einzelketten-Antikörper mit humanem Cmu3- und Cmu4- Domänen
AU2003210060B2 (en) 2002-03-22 2010-02-25 Aprogen, Inc. Humanized antibody and process for preparing same
EP1885396A2 (en) * 2005-05-04 2008-02-13 Quark Pharmaceuticals, Inc. Recombinant antibodies against cd55 and cd59 and uses thereof
HUE029021T2 (en) * 2005-06-21 2017-02-28 Xoma (Us) Llc IL-1beta-binding antibodies and fragments thereof
ATE452913T1 (de) * 2005-08-26 2010-01-15 Pls Design Gmbh Bivalente igy antikörperkonstrukte für diagnostische und therapeutische anwendungen
EP1962961B1 (en) * 2005-11-29 2013-01-09 The University Of Sydney Demibodies: dimerisation-activated therapeutic agents
US8273030B2 (en) 2005-12-01 2012-09-25 Atcor Medical Pty Ltd Method of estimating pulse wave velocity
CA2646329C (en) * 2006-03-20 2018-07-03 The Regents Of The University Of California Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
MX2009011342A (es) * 2007-04-20 2009-11-05 Invista Tech Sarl Fileta compacta de desenrollamiento continuo por encima con control de tension.
JP5511654B2 (ja) * 2007-05-31 2014-06-04 ゲンマブ エー／エス 分子操作により得られた組換え非グリコシル化一価半抗体
EP2116555A1 (en) * 2008-05-08 2009-11-11 Bayer Schering Pharma Aktiengesellschaft Use of a radioactively labelled molecule specifically binding to ED-B fibronectin in a method of treatment of Hodgkin lymphoma
DE102009047243A1 (de) * 2009-11-27 2011-06-01 Orgentec Diagnostika Gmbh Monospezifische Polypeptidreagenzien

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000516452A (ja) * 1996-07-16 2000-12-12 プリュックテュン，アンドレアス 可溶性が増大した免疫グロブリンスーパーファミリードメインおよびフラグメント
JP2003501096A (ja) * 1999-06-07 2003-01-14 ネオルクス コーポレイション ストレプトアビジン発現性遺伝子融合およびその使用方法
WO2005017148A1 (en) * 2003-07-26 2005-02-24 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
JP2007528194A (ja) * 2003-07-26 2007-10-11 トルビオン・ファーマシューティカルズ・インコーポレイテッド 結合構築体およびその使用方法
JP2009544300A (ja) * 2006-07-25 2009-12-17 ユセベ ファルマ ソシエテ アノニム 単鎖Ｆｃポリペプチド
WO2008131242A1 (en) * 2007-04-18 2008-10-30 Zymogenetics, Inc. Single chain fc, methods of making and methods of treatment

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
ANDERSEN, C.B. ET AL., PROTEIN SCI., vol. 19, JPN6016017609, 15 December 2009 (2009-12-15), pages 279 - 290, ISSN: 0003315611 *
ARNDT, K.M. ET AL., BIOCHEMISTRY, vol. 37, JPN6015039471, 1998, pages 12918 - 12926, ISSN: 0003166010 *
DESPLANCQ, D. ET AL., PROTEIN ENG., vol. 7, no. 8, JPN6016017600, 1994, pages 1027 - 1033, ISSN: 0003315607 *
DIMITROV, D.S., MABS, vol. 1, no. 1, JPN6014053642, 1 January 2009 (2009-01-01), pages 26 - 28, ISSN: 0002968150 *
FAST, J.L. ET AL., BIOCHEMISTRY, vol. 48, JPN6016017605, 11 September 2009 (2009-09-11), pages 11724 - 11736, ISSN: 0003315608 *
HU, S. ET AL., CANCER RES., vol. 56, JPN6016017603, 1996, pages 3055 - 3061, ISSN: 0003315609 *
JUNG, S. AND PLUCKTHUN, A., PROTEIN ENG., vol. 10, no. 8, JPN6016017607, 1997, pages 959 - 966, ISSN: 0003315610 *
LI, E. ET AL., PROTEIN ENG., vol. 10, no. 6, JPN6014053644, 1997, pages 731 - 736, ISSN: 0002968151 *
OLAFSEN, T. ET AL., PROTEIN ENG. DES. SEL., vol. 17, no. 4, JPN6014053649, 2004, pages 315 - 323, ISSN: 0002968154 *
SHAO, C. AND ZHANG, J., CELL. MOL. IMMUNOL., vol. 5, no. 4, JPN6014053645, 2008, pages 299 - 306, ISSN: 0002968152 *
TURNER, D.J. ET AL., J. IMMUNOL. METHODS, vol. 205, JPN6015039473, 1997, pages 43 - 54, ISSN: 0003166011 *
WU, A.M. ET AL., PROTEIN ENG., vol. 14, no. 12, JPN6014053647, 2001, pages 1025 - 1033, ISSN: 0002968153 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022528030A (ja) * 2019-01-07 2022-06-08 トーマス・ジェファーソン・ユニバーシティ 多機能性融合タンパク質及びその使用
JP7587505B2 (ja) 2019-01-07 2024-11-20 トーマス・ジェファーソン・ユニバーシティ 多機能性融合タンパク質及びその使用
US12497439B2 (en) 2019-01-07 2025-12-16 Thomas Jefferson University Multi-functional fusion proteins and uses thereof

Also Published As

Publication number Publication date
US9815891B2 (en) 2017-11-14
CA2782016A1 (en) 2011-06-03
US9163079B2 (en) 2015-10-20
DE102009047243A1 (de) 2011-06-01
CA2782016C (en) 2020-01-07
EP2504359B1 (de) 2016-03-23
AU2010323144B2 (en) 2013-11-07
DK2504359T3 (da) 2016-07-25
AU2010323144A1 (en) 2012-07-12
US20160046703A1 (en) 2016-02-18
WO2011064257A2 (de) 2011-06-03
US20120276099A1 (en) 2012-11-01
WO2011064257A3 (de) 2011-08-11
EP2504359A2 (de) 2012-10-03

Similar Documents

Publication Publication Date Title
US9815891B2 (en) Monospecific polypeptide reagents
KR102662387B1 (ko) B7-h3 항체, 이의 항원-결합 단편 및 이의 의학적 용도
JP6165713B2 (ja) インスリン様増殖因子１に特異的に結合する抗体
CN110256569B (zh) 具有交换结合区取向的双重可变区抗体样结合蛋白
KR102651965B1 (ko) 신규 항 cd3 항체
JP2023509212A (ja) 新型ポリペプチド複合物
WO2021047559A1 (zh) 一种断裂型内含肽、使用其的重组多肽的制备方法
US20240199726A1 (en) Antibodies targeting talaromyces marneffei mp1p protein and methods of use thereof
US11505614B2 (en) Antibodies binding to soluble BCMA
TWI789399B (zh) 不對稱異二聚fc-scfv融合抗globo h及抗cd3雙特異性抗體及其於癌症治療上之用途
CN109336973B (zh) 抗转铁蛋白抗体及其用途
US20220235139A1 (en) Anti-csf-ir antibody
US20230324388A1 (en) Antibody for porcine reproductive and respiratory syndrome virus and uses thereof
RU2737466C1 (ru) Гуманизированное нейтрализующее антитело к интерферону-бета человека
EP4194054A1 (en) Camelid antibodies for use in therapy and diagnosis
CN120718146A (zh) 抗人TNF-β的单克隆抗体及其应用
WO2024255756A1 (zh) 基于共同轻链产生双特异性抗体的方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131113

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20131113

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141222

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150323

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150416

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151005

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160104

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160516

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20160601

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160601